Back to Search
Start Over
A case of unresectable combined hepatocellular and cholangiocarcinoma treated with atezolizumab plus bevacizumab.
- Source :
- Clinical Case Reports; Jul2022, Vol. 10 Issue 7, p1-8, 8p
- Publication Year :
- 2022
-
Abstract
- An 81‐year‐old man initially underwent right hepatic lobectomy for liver cancer and was pathologically diagnosed with combined hepatocellular and cholangiocarcinoma (CHC). At 13 months after resection, multiple lymph node metastases were observed. We started atezolizumab plus bevacizumab (Atez/Bev), achieving a 7.5‐month progression‐free survival. Atez/Bev might exhibit efficacy for CHC patients. [ABSTRACT FROM AUTHOR]
- Subjects :
- BEVACIZUMAB
ATEZOLIZUMAB
CHOLANGIOCARCINOMA
LIVER cancer
LYMPHATIC metastasis
Subjects
Details
- Language :
- English
- ISSN :
- 20500904
- Volume :
- 10
- Issue :
- 7
- Database :
- Complementary Index
- Journal :
- Clinical Case Reports
- Publication Type :
- Academic Journal
- Accession number :
- 158200724
- Full Text :
- https://doi.org/10.1002/ccr3.6129